Patients underwent a reduced-dose (cohort 1) or standard-dose (cohort 2) lymphodepletion regimen (LDR). The primary end point was investigator-assessed overall response rate (ORR). Safety was assessed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback